Is Neurocrine Biosciences Inc halal to invest in?

As of July 2026, Neurocrine Biosciences Inc NBIX is classified as halal according to Musaffa’s Shariah screening methodology. This classification is based on an assessment of the company’s business activities and financial ratios against Islamic investment guidelines.

Is Neurocrine Biosciences Inc a Shariah-compliant stock?

A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes Neurocrine Biosciences Inc using these criteria to determine its compliance status.

Can Muslims buy shares of Neurocrine Biosciences Inc?

Muslim investors may consider investing in Neurocrine Biosciences Inc if it meets Shariah compliance standards. Investors typically review the company's business activities, debt levels, and non-permissible income before making a decision.

Why is Neurocrine Biosciences Inc classified as HALAL?

Musaffa determines the Shariah status of Neurocrine Biosciences Inc by analyzing whether the company's core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.

How often is the Shariah compliance for Neurocrine Biosciences Inc updated?

The Shariah compliance status of Neurocrine Biosciences Inc may be updated periodically when new financial statements, earnings reports, or business activity information become available.

Can a halal stock like Neurocrine Biosciences Inc become non-compliant?

Yes. A stock that is currently Shariah-compliant may become non-compliant if the company's financial ratios exceed Shariah thresholds or its business activities change.

Where can I check the Shariah status of Neurocrine Biosciences Inc?

You can check the latest Shariah compliance status of Neurocrine Biosciences Inc on Musaffa's stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.

NBIX Shariah Compliance

Screening Methodology: AAOIFI

As of July 2026, Neurocrine Biosciences Inc is classified as halal.

HALAL

Report Source: 2026 1st Quarter Report

Neurocrine Biosciences Inc. Stock Analysis NBIX

United States Health Care Large Cap Report: Q1, 2026

Neurocrine Biosciences, Inc. is a neuroscience-focused, biopharmaceutical company, which engages in the research and development, commercialization, and sale of pharmaceuticals for the treatment of neurological, neuroendocrine, and neuropsychiatric disorders. The company is headquartered in San Diego, California and currently employs 2,000 full-time employees. The firm is engaged in discovering and developing treatments for patients with under-addressed neurological, neuroendocrine and neuropsychiatric disorders. Its diverse portfolio includes the United States Food and Drug Administration-approved treatments for tardive dyskinesia, chorea associated with Huntington’s disease, endometriosis and uterine fibroids, as well as a robust pipeline, including multiple compounds in mid-to late-phase clinical development across its core therapeutic areas. Its commercial products include INGREZZA, ALKINDI, EFMODY, Orilissa, and Oriahnn. INGREZZA is marketed as DYSVAL (valbenazine) in Japan and REMLEAS (valbenazine) in other select Asian markets, where Mitsubishi Tanabe Pharma Corporation retains commercialization rights. ALKINDI is marketed as ALKINDI SPRINKLE (hydrocortisone) in the United States, where Eton Pharmaceuticals, Inc. retains commercialization rights.

Key Statistics of Neurocrine Biosciences Inc (NBIX)

Key statistics in the stock market are essential financial indicators that measure a company's performance, valuation, profitability, and risk.

Today's Range

$174.27$181.00

Today's Open

$178.87

Volume

977.54K

P/E Ratio (TTM)

37.29

52 Week Range

$122.14$181.18

Market Cap

17.92B

Avg. Volume

1.13M

Dividend Yield

Financial Metrics & Statements of Neurocrine Biosciences Inc (NBIX)

Super Investors Invested in Neurocrine Biosciences Inc (NBIX)

FAQ's for Neurocrine Biosciences Inc (NBIX)

As of July 2026, Neurocrine Biosciences Inc NBIX is classified as halal according to Musaffa’s Shariah screening methodology. This classification is based on an assessment of the company’s business activities and financial ratios against Islamic investment guidelines.
A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes Neurocrine Biosciences Inc using these criteria to determine its compliance status.
Muslim investors may consider investing in Neurocrine Biosciences Inc if it meets Shariah compliance standards. Investors typically review the company’s business activities, debt levels, and non-permissible income before making a decision.
Musaffa determines the Shariah status of Neurocrine Biosciences Inc by analyzing whether the company’s core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.
The Shariah compliance status of Neurocrine Biosciences Inc may be updated periodically when new financial statements, earnings reports, or business activity information become available.
Yes. A stock that is currently Shariah-compliant may become non-compliant if the company’s financial ratios exceed Shariah thresholds or its business activities change.
You can check the latest Shariah compliance status of Neurocrine Biosciences Inc on Musaffa’s stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.